Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1999-3-4
|
| pubmed:abstractText |
Recent studies have shown that Exisulind, a sulfone metabolite of the nonsteroidal anti-inflammatory drug (NSAID) sulindac, has inhibitory activity in vitro with cultured human prostate cancer cells. To determine whether this effect might be pharmacologically relevant in vivo, we tested whether Exisulind therapy could suppress the growth of human prostate cancer cells in a nude mouse xenograft model.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0090-4295
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
53
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
440-5
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:9933075-Animals,
pubmed-meshheading:9933075-Antineoplastic Agents,
pubmed-meshheading:9933075-Apoptosis,
pubmed-meshheading:9933075-Cell Division,
pubmed-meshheading:9933075-Humans,
pubmed-meshheading:9933075-Male,
pubmed-meshheading:9933075-Mice,
pubmed-meshheading:9933075-Mice, Nude,
pubmed-meshheading:9933075-Neoplasm Transplantation,
pubmed-meshheading:9933075-Prostatic Neoplasms,
pubmed-meshheading:9933075-Sulindac
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis.
|
| pubmed:affiliation |
Department of Urology, and Comprehensive Cancer Center, School of Medicine, Columbia University, New York, New York, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|